Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Peter Scheurich

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Physiology

Signal Transduction

Anatomy

Living Beings

Mice

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
34
Wajant, Harald
19
Grell, Matthias
16
Pfizenmaier, Klaus
7
Peters, Nathalie
7
Siegmund, Daniela
7
Schwenzer, Ralph
6
Henkler, Frank
5
Fotin-Mleczek, Mariola
5
Schubert, G
5
Mühlenbeck, F
5
Moosmayer, Dieter
5
Zimmermann, Gudrun
4
Siemienski, K
4
Krippner-Heidenreich, Anja
4
Haas, E

Sign-in to see all Coauthors

Publications

TOP 3
Messerschmidt Sylvia K E; Musyanovych Anna; Altvater Martin; Scheurich Peter; Pfizenmaier Klaus; Landfester Katharina; Kontermann Roland E
Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
Krippner-Heidenreich Anja; Grunwald Ingo; Zimmermann Gudrun; Kühnle Marie; Gerspach Jeannette; Sterns Theobald; Shnyder Steve D; Gill Jason H; Männel Daniela N; Pfizenmaier Klaus; Scheurich Peter
Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity.
Kontermann Roland E; Münkel Sabine; Neumeyer Jens; Müller Dafne; Branschädel Marcus; Scheurich Peter; Pfizenmaier Klaus
A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Peter Scheurich (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Messerschmidt Sylvia K E; Musyanovych Anna; Altvater Martin; Scheurich Peter; Pfizenmaier Klaus; Landfester Katharina; Kontermann Roland E
Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
Journal of controlled release : official journal of the Controlled Release Society 2009;137(1):69-77.
2008: Krippner-Heidenreich Anja; Grunwald Ingo; Zimmermann Gudrun; Kühnle Marie; Gerspach Jeannette; Sterns Theobald; Shnyder Steve D; Gill Jason H; Männel Daniela N; Pfizenmaier Klaus; Scheurich Peter
Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(12):8176-83.
2008: Kontermann Roland E; Münkel Sabine; Neumeyer Jens; Müller Dafne; Branschädel Marcus; Scheurich Peter; Pfizenmaier Klaus
A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(3):225-34.
2007: Eissing Thomas; Waldherr Steffen; Allgöwer Frank; Scheurich Peter; Bullinger Eric
Steady state and (bi-) stability evaluation of simple protease signalling networks.
Bio Systems 2007;90(3):591-601.
2007: Eissing Thomas; Waldherr Steffen; Allgöwer Frank; Scheurich Peter; Bullinger Eric
Response to bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores.
Biophysical journal 2007;92(9):3332-4.
2005: Bryde Susanne; Grunwald Ingo; Hammer Angela; Krippner-Heidenreich Anja; Schiestel Thomas; Brunner Herwig; Tovar Günter E M; Pfizenmaier Klaus; Scheurich Peter
Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses.
Bioconjugate chemistry 2005;16(6):1459-67.
2005: Fotin-Mleczek Mariola; Welte Stefan; Mader Oliver; Duchardt Falk; Fischer Rainer; Hufnagel Hansjörg; Scheurich Peter; Brock Roland
Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization.
Journal of cell science 2005;118(Pt 15):3339-51.
2005: Till Andreas; Rosenstiel Philip; Krippner-Heidenreich Anja; Mascheretti-Croucher Silvia; Croucher Peter J P; Schäfer Heiner; Scheurich Peter; Seegert Dirk; Schreiber Stefan
The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression.
The Journal of biological chemistry 2005;280(7):5994-6004.
2004: Eissner Günther; Kolch Walter; Scheurich Peter
Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.
Cytokine & growth factor reviews 2004;15(5):353-66.
2004: Kreuz Sebastian; Siegmund Daniela; Rumpf Jost-Julian; Samel Dierk; Leverkus Martin; Janssen Ottmar; Häcker Georg; Dittrich-Breiholz Oliver; Kracht Michael; Scheurich Peter; Wajant Harald
NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP.
The Journal of cell biology 2004;166(3):369-80.
2004: Eissing Thomas; Conzelmann Holger; Gilles Ernst D; Allgöwer Frank; Bullinger Eric; Scheurich Peter
Bistability analyses of a caspase activation model for receptor-induced apoptosis.
The Journal of biological chemistry 2004;279(35):36892-7.
2004: Fotin-Mleczek Mariola; Henkler Frank; Hausser Angelika; Glauner Heike; Samel Dierk; Graness Angela; Scheurich Peter; Mauri Davide; Wajant Harald
Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation.
The Journal of biological chemistry 2004;279(1):677-85.
2004: Wajant H; Scheurich P
Analogies between Drosophila and mammalian TRAF pathways.
Progress in molecular and subcellular biology 2004;34():47-72.
2003: Henkler Frank; Baumann Bernd; Fotin-Mleczek Mariola; Weingärtner Monika; Schwenzer Ralph; Peters Nathalie; Graness Angela; Wirth Thomas; Scheurich Peter; Schmid Johannes A; Wajant Harald
Caspase-mediated cleavage converts the tumor necrosis factor (TNF) receptor-associated factor (TRAF)-1 from a selective modulator of TNF receptor signaling to a general inhibitor of NF-kappaB activation.
The Journal of biological chemistry 2003;278(31):29216-30.
2003: Wajant Harald; Pfizenmaier Klaus; Scheurich Peter
Non-apoptotic Fas signaling.
Cytokine & growth factor reviews 2003;14(1):53-66.
2003: Wajant H; Pfizenmaier K; Scheurich P
Tumor necrosis factor signaling.
Cell death and differentiation 2003;10(1):45-65.
2002: Holtmann Martin H; Douni Eleni; Schütz Michael; Zeller Geraldine; Mudter Jonas; Lehr Hans-Anton; Gerspach Jeanette; Scheurich Peter; Galle Peter R; Kollias George; Neurath Markus F
Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo.
European journal of immunology 2002;32(11):3142-51.
2002: Krippner-Heidenreich Anja; Tübing Fabian; Bryde Susanne; Willi Sylvia; Zimmermann Gudrun; Scheurich Peter
Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction.
The Journal of biological chemistry 2002;277(46):44155-63.
2002: Glauner Heike; Siegmund Daniela; Motejadded Hassan; Scheurich Peter; Henkler Frank; Janssen Ottmar; Wajant Harald
Intracellular localization and transcriptional regulation of tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4).
European journal of biochemistry / FEBS 2002;269(19):4819-29.
2002: Wajant H; Pfizenmaier K; Scheurich P
TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy.
Apoptosis : an international journal on programmed cell death 2002;7(5):449-59.
2002: Weingärtner Monika; Siegmund Daniela; Schlecht Ulrich; Fotin-Mleczek Mariola; Scheurich Peter; Wajant Harald
Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosis.
The Journal of biological chemistry 2002;277(38):34853-9.
2002: Fotin-Mleczek Mariola; Henkler Frank; Samel Dierk; Reichwein Monica; Hausser Angelika; Parmryd Ingela; Scheurich Peter; Schmid Johannes A; Wajant Harald
Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8.
Journal of cell science 2002;115(Pt 13):2757-70.
2001: Siegmund D; Hausser A; Peters N; Scheurich P; Wajant H
Tumor necrosis factor (TNF) and phorbol ester induce TNF-related apoptosis-inducing ligand (TRAIL) under critical involvement of NF-kappa B essential modulator (NEMO)/IKKgamma.
The Journal of biological chemistry 2001;276(47):43708-12.
2001: Siegmund D; Mauri D; Peters N; Juo P; Thome M; Reichwein M; Blenis J; Scheurich P; Tschopp J; Wajant H
Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway.
The Journal of biological chemistry 2001;276(35):32585-90.
2001: Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
Oncogene 2001;20(30):4101-6.
2001: Wajant H; Henkler F; Scheurich P
The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators.
Cellular signalling 2001;13(6):389-400.
2001: Kreuz S; Siegmund D; Scheurich P; Wajant H
NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.
Molecular and cellular biology 2001;21(12):3964-73.
2001: Clauss M; Sunderkötter C; Sveinbjörnsson B; Hippenstiel S; Willuweit A; Marino M; Haas E; Seljelid R; Scheurich P; Suttorp N; Grell M; Risau W
A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability.
Blood 2001;97(5):1321-9.
2001: Bartke T; Siegmund D; Peters N; Reichwein M; Henkler F; Scheurich P; Wajant H
p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells.
Oncogene 2001;20(5):571-80.
2001: Wajant H; Scheurich P
Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling.
The international journal of biochemistry & cell biology 2001;33(1):19-32.
2000: Mühlenbeck F; Schneider P; Bodmer J L; Schwenzer R; Hauser A; Schubert G; Scheurich P; Moosmayer D; Tschopp J; Wajant H
The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation.
The Journal of biological chemistry 2000;275(41):32208-13.
2000: Wajant H; Haas E; Schwenzer R; Muhlenbeck F; Kreuz S; Schubert G; Grell M; Smith C; Scheurich P
Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD).
The Journal of biological chemistry 2000;275(32):24357-66.
2000: Eissner G; Kirchner S; Lindner H; Kolch W; Janosch P; Grell M; Scheurich P; Andreesen R; Holler E
Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(12):6193-8.
1999: Schwenzer R; Siemienski K; Liptay S; Schubert G; Peters N; Scheurich P; Schmid R M; Wajant H
The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappaB and c-Jun N-terminal kinase.
The Journal of biological chemistry 1999;274(27):19368-74.
1999: Schneider P; Schwenzer R; Haas E; Mühlenbeck F; Schubert G; Scheurich P; Tschopp J; Wajant H
TWEAK can induce cell death via endogenous TNF and TNF receptor 1.
European journal of immunology 1999;29(6):1785-92.
1999: Haas E; Grell M; Wajant H; Scheurich P
Continuous autotropic signaling by membrane-expressed tumor necrosis factor.
The Journal of biological chemistry 1999;274(25):18107-12.
1999: Grell M; Zimmermann G; Gottfried E; Chen C M; Grünwald U; Huang D C; Wu Lee Y H; Dürkop H; Engelmann H; Scheurich P; Wajant H; Strasser A
Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF.
The EMBO journal 1999;18(11):3034-43.
1999: Wajant H; Grell M; Scheurich P
TNF receptor associated factors in cytokine signaling.
Cytokine & growth factor reviews 1999;10(1):15-26.
1999: Dri P; Haas E; Cramer R; Menegazzi R; Gasparini C; Martinelli R; Scheurich P; Patriarca P
Role of the 75-kDa TNF receptor in TNF-induced activation of neutrophil respiratory burst.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(1):460-6.
1998: Wajant H; Mühlenbeck F; Scheurich P
Identification of a TRAF (TNF receptor-associated factor) gene in Caenorhabditis elegans.
Journal of molecular evolution 1998;47(6):656-62.
1998: Mühlenbeck F; Haas E; Schwenzer R; Schubert G; Grell M; Smith C; Scheurich P; Wajant H
TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways.
The Journal of biological chemistry 1998;273(49):33091-8.
1998: Wajant H; Pfeffer K; Pfizenmaier K; Scheurich P
Tumor necrosis factors in 1998.
Cytokine & growth factor reviews 1998;9(3-4):297-302.
1998: Weiss T; Grell M; Siemienski K; Mühlenbeck F; Dürkop H; Pfizenmaier K; Scheurich P; Wajant H
TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(6):3136-42.
1998: Grell M; Becke F M; Wajant H; Männel D N; Scheurich P
TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1.
European journal of immunology 1998;28(1):257-63.
1998: Grell M; Wajant H; Zimmermann G; Scheurich P
The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(2):570-5.
1998: Wajant H; Johannes F J; Haas E; Siemienski K; Schwenzer R; Schubert G; Weiss T; Grell M; Scheurich P
Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction.
Current biology : CB 1998;8(2):113-6.
1997: Siemienski K; Peters N; Scheurich P; Wajant H
Organization of the human tumour necrosis factor receptor-associated factor 1 (TRAF1) gene and mapping to chromosome 9q33-34.
Gene 1997;195(1):35-9.
1997: Weiss T; Grell M; Hessabi B; Bourteele S; Müller G; Scheurich P; Wajant H
Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(5):2398-404.
1997: Lazdins J K; Grell M; Walker M R; Woods-Cook K; Scheurich P; Pfizenmaier K
Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells.
The Journal of experimental medicine 1997;185(1):81-90.
1995: Grell M; Douni E; Wajant H; Löhden M; Clauss M; Maxeiner B; Georgopoulos S; Lesslauer W; Kollias G; Pfizenmaier K; Scheurich P
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor.
Cell 1995;83(5):793-802.
1995: Moosmayer D; Dübel S; Brocks B; Watzka H; Hampp C; Scheurich P; Little M; Pfizenmaier K
A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity.
Therapeutic immunology 1995;2(1):31-40.
1994: Moosmayer D; Dinkel A; Gerlach E; Hessabi B; Grell M; Pfizenmaier K; Scheurich P
Coexpression of the human TNF receptors TR60 and TR80 in insect cells: analysis of receptor complex formation.
Lymphokine and cytokine research 1994;13(5):295-301.
1994: Grell M; Krammer P H; Scheurich P
Segregation of APO-1/Fas antigen- and tumor necrosis factor receptor-mediated apoptosis.
European journal of immunology 1994;24(10):2563-6.
1994: Grell M; Zimmermann G; Hülser D; Pfizenmaier K; Scheurich P
TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(5):1963-72.
1994: Moosmayer D; Gerlach E; Böttinger H; Scheurich P; Pfizenmaier K
Expression of complete human IFN-gamma receptor and its extracellular domain in insect cells: purification and characterization of the recombinant proteins.
Lymphokine and cytokine research 1994;13(2):147-53.
1993: Grell M; Scheurich P; Meager A; Pfizenmaier K
TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis.
Lymphokine and cytokine research 1993;12(3):143-8.
1992: Krönke M; Schütze S; Scheurich P; Pfizenmaier K
TNF signal transduction and TNF-responsive genes.
Immunology series 1992;56():189-216.
1991: Vehmeyer K; Scheurich P; Eibl H; Unger C
Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin 2.
Cellular immunology 1991;137(1):232-8.
1990: Thoma B; Grell M; Pfizenmaier K; Scheurich P
Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses.
The Journal of experimental medicine 1990;172(4):1019-23.
1990: Fischer T; Thoma B; Scheurich P; Pfizenmaier K
Glycosylation of the human interferon-gamma receptor. N-linked carbohydrates contribute to structural heterogeneity and are required for ligand binding.
The Journal of biological chemistry 1990;265(3):1710-7.
1990: Krönke M; Schütze S; Scheurich P; Meichle A; Hensel G; Thoma B; Kruppa G; Pfizenmaier K
Tumour necrosis factor signal transduction.
Cellular signalling 1990;2(1):1-8.
1989: Scheurich P; Köbrich G; Pfizenmaier K
Antagonistic control of tumor necrosis factor receptors by protein kinases A and C. Enhancement of TNF receptor synthesis by protein kinase A and transmodulation of receptors by protein kinase C.
The Journal of experimental medicine 1989;170(3):947-58.
1989: Schütze S; Scheurich P; Pfizenmaier K; Krönke M
Tumor necrosis factor signal transduction. Tissue-specific serine phosphorylation of a 26-kDa cytosolic protein.
The Journal of biological chemistry 1989;264(6):3562-7.
1989: Bartsch H H; Pfizenmaier K; Hanusch A; Scheurich P; Ucer U; Nagel G A
Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-alpha correlates with the degree of receptor down-regulation.
International journal of cancer. Journal international du cancer 1989;43(2):235-40.
1988: Krönke M; Hensel G; Schlüter C; Scheurich P; Schütze S; Pfizenmaier K
Tumor necrosis factor and lymphotoxin gene expression in human tumor cell lines.
Cancer research 1988;48(19):5417-21.
1988: Pfizenmaier K; Wiegmann K; Scheurich P; Krönke M; Merlin G; Aguet M; Knowles B B; Ucer U
High affinity human IFN-gamma-binding capacity is encoded by a single receptor gene located in proximity to c-ros on human chromosome region 6q16 to 6q22.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(3):856-60.
1988: Schütze S; Scheurich P; Schlüter C; Ucer U; Pfizenmaier K; Krönke M
Tumor necrosis factor-induced changes of gene expression in U937 cells. Differentiation-dependent plasticity of the responsive state.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(9):3000-5.
1988: Schütze S; Nottrott S; Scheurich P; Krönke M; Pfizenmaier K
Mechanisms of TNF resistance: identification of membrane phosphoproteins associated with a dominant resistant phenotype in lymphoid-myeloid somatic cell hybrids.
Molecular biotherapy 1988;1(2):96-102.
1987: Unglaub R; Maxeiner B; Thoma B; Pfizenmaier K; Scheurich P
Downregulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators.
The Journal of experimental medicine 1987;166(6):1788-97.
1987: Ucer U; Scheurich P; Bartsch H; Berkovic D; Ertel C; Pfizenmaier K
Specific membrane receptors for human interferon-gamma (IFN-gamma).
Behring Institute Mitteilungen 1987;(81):88-97.
1987: Scheurich P; Thoma B; Ucer U; Pfizenmaier K
Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(6):1786-90.
1987: Pfizenmaier K; Scheurich P; Schlüter C; Krönke M
Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(3):975-80.
1986: Ucer U; Bartsch H; Scheurich P; Berkovic D; Ertel C; Pfizenmaier K
Quantitation and characterization of gamma-interferon receptors on human tumor cells.
Cancer research 1986;46(10):5339-43.
1986: Scheurich P; Krönke M; Schlüter C; Ucer U; Pfizenmaier K
Noncytocidal mechanisms of action of tumor necrosis factor-alpha on human tumor cells: enhancement of HLA gene expression synergistic with interferon-gamma.
Immunobiology 1986;172(3-5):291-300.
1986: Berkovic D; Bartsch H H; Scheurich P; Ucer U; Pfizenmaier K
IFN-gamma receptors on human tumor cells: relationship between receptor ligand interactions and induction of IFN-gamma response.
Immunobiology 1986;172(3-5):243-9.
1986: Scheurich P; Ucer U; Krönke M; Pfizenmaier K
Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines.
International journal of cancer. Journal international du cancer 1986;38(1):127-33.
1985: Scheurich P; Ucer U; Wrann M; Pfizenmaier K
Early events during primary activation of T cells: antigen receptor cross-linking and interleukin 1 initiate proliferative response of human T cells.
European journal of immunology 1985;15(11):1091-5.
1985: Pfizenmaier K; Bartsch H; Scheurich P; Seliger B; Ucer U; Vehmeyer K; Nagel G A
Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth.
Cancer research 1985;45(8):3503-9.
1985: Ucer U; Bartsch H; Scheurich P; Pfizenmaier K
Biological effects of gamma-interferon on human tumor cells: quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression.
International journal of cancer. Journal international du cancer 1985;36(1):103-8.
1985: Däubener W; von Steldern D; Maxeiner B; Scheurich P; Pfizenmaier K
Postnatal development of functional T cell subsets in the mouse: a frequency analysis of mitogen reactive precursors of proliferating, of cytotoxic and of IL 2 producing T cells.
Immunobiology 1985;169(5):472-85.
1984: Pfizenmaier K; Scheurich P; Däubener W; Krönke M; Röllinghoff M; Wagner H
Quantitative representation of all T cells committed to develop into cytotoxic effector cells and/or interleukin 2 activity-producing helper cells within murine T lymphocyte subsets.
European journal of immunology 1984;14(1):33-9.

Sign-in to see more